Arthritis drugs effective in improving survival in sickest COVID-19 patients, NIHR
Results from the REMAP-CAP clinical trial evaluated the effect of treatments on a combination of survival and length of time patients need support in an intensive care unit (ICU). Patients receiving tocilizumab and a second drug called sarilumab - both types of immune modulators - have a significant impact on patient survival and can reduce the relative risk of death by 24% when administered to patients within 24 hours of entering intensive care.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news
More News: Actemra | Arthritis | Clinical Trials | COVID-19 | Health | Intensive Care | National Institute for Health Research (NIHR) | Rheumatology